HEK293/Human OX40 Ligand / TNFSF4 Stable Cell Line
描述（Description）
HEK293/Human OX40 Ligand / TNFSF4 Stable Cell Line
應(yīng)用說(shuō)明（Application）
Binding assay by FACS and cell based ELISA
生長(zhǎng)特性（Growth Properties）
Adherent
篩選標(biāo)記（Selection Marker）
Puromycin (10 μg/mL)
培養(yǎng)基（Culture Medium）
DMEM medium + 10% FBS
凍存液（Freeze Medium）
10% DMSO + 90% FBS
裝量（Quantity）
1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.
存儲(chǔ)（Storage）
Frozen in liquid nitrogen.
支原體檢測(cè)（Mycoplasma Testing）
Negative
無(wú)菌檢測(cè)（Sterility Testing）
Negative
使用說(shuō)明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
關(guān)鍵字： OX40 Ligand穩(wěn)定細(xì)胞系;OX40 Ligand細(xì)胞系;OX40 Ligand細(xì)胞株;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。